CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells
| dc.contributor.author | Lozada Martinez, Ivan David | |
| dc.contributor.author | Bolaño Romero, Maria Paz | |
| dc.contributor.author | Lambis Anaya, Lina | |
| dc.contributor.author | Liscano, Yamil | |
| dc.contributor.author | Suarez Causado, Amileth | |
| dc.date.accessioned | 2025-07-11T20:25:38Z | |
| dc.date.available | 2025-07-11T20:25:38Z | |
| dc.date.issued | 2023 | |
| dc.description | Antecedentes: Existe muy poca evidencia sobre biomarcadores para evaluar el comportamiento clínico y la respuesta terapéutica en cáncer de recto (CR) con expresión positiva de células madre cancerígenas (CSCs). Métodos: Se realizó un estudio prospectivo exploratorio que incluyó muestras frescas de tejido tumoral de 109 pacientes diagnosticados de CR primario. Las características sociodemográficas, patológicas y clínicas se recogieron de los registros médicos y de la encuesta. La proteína OCT4 se aisló mediante la técnica Western Blot. Se calcularon los valores de ΔCEA, ΔOCT4 y ΔOCT4/GUSB evaluando los cambios antes y después de la quimioterapia, con el objetivo de evaluar la respuesta terapéutica. Resultados: Los pacientes tenían una edad media de 69,9 años, siendo el 55% (n=60) varones. Aproximadamente el 63,3% de los tumores eran indiferenciados, y la clasificación por estadios más frecuente fue el estadio patológico III (n=64; 58,7%). La expresión inicial positiva se observó en el 77,1% de los pacientes (n=84), y la mediana de ΔCEA fue de -1,03 (-3,82 - 0,84) ng/ml, encontrándose niveles elevados (< -0,94 ng/ml) en el 51,4% de los sujetos (n=56). Ser OCT4 positivo y tener un valor elevado de ΔCEA se asociaron significativamente con un fenotipo tumoral indiferenciado (p=0,002), un estadio avanzado de progresión tumoral (p <0,001) y valores negativos de ΔOCT4 (p <0,001) (sugestivos de mala respuesta terapéutica) en comparación con aquellos sin este estado. | |
| dc.description.abstract | Background: There is very limited evidence on biomarkers for evaluating the clinical behavior and therapeutic response in rectal cancer (RC) with positive expression of cancer stem cells (CSCs). Methods: An exploratory prospective study was conducted, which included fresh samples of tumor tissue from 109 patients diagnosed with primary RC. Sociodemographic, pathological and clinical characteristics were collected from medical records and survey. The OCT4 protein was isolated using the Western Blot technique. It was calculated the ΔCEA, ΔOCT4, and ΔOCT4/GUSB values by assessing the changes before and after chemotherapy, aiming to evaluate the therapeutic response. Results: Patients had an average age of 69.9 years, with 55% (n=60) being male. Approximately 63.3% of the tumors were undifferentiated, and the most frequent staging classification was pathological stage III (n=64; 58.7%). Initial positive expression was observed in 77.1% of the patients (n=84), and the median ΔCEA was -1.03 (-3.82 - 0.84) ng/ml, with elevated levels (< -0.94 ng/ml) found in 51.4% of the subjects (n=56). Being OCT4 positive and having an elevated ΔCEA value were significantly associated with undifferentiated tumor phenotype (p=0.002), advanced tumor progression stage (p <0.001), and negative values of ΔOCT4 (p <0.001) (suggestive of poor therapeutic response) compared to those without this status. | |
| dc.identifier.citation | Lozada-Martinez, I. D., Bolaño-Romero, M. P., Lambis-Anaya, L., Liscano, Y., & Suarez-Causado, A. (2023). CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells. Frontiers in Oncology, 13(September), 1–17. https://doi.org/10.3389/fonc.2023.1258863 | |
| dc.identifier.issn | 2234943X | |
| dc.identifier.uri | https://repositorio.usc.edu.co/handle/20.500.12421/7408 | |
| dc.language.iso | en | |
| dc.publisher | Frontiers Media SA | |
| dc.subject | carcinoembryonic antigen | |
| dc.subject | drug therapy | |
| dc.subject | human POU5F1 protein | |
| dc.subject | neoplasm staging | |
| dc.subject | prognosis | |
| dc.subject | rectal neoplasms | |
| dc.title | CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells | |
| dc.type | Article |